Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Rating of "Buy" from Brokerages

Key Points

• Maze Therapeutics has an average broker rating of "Buy" from 11 covering analysts, with a consensus 1-year price target of $66.00.
• Recent analyst actions were mixed but mostly positive, including upgrades from Mizuho to strong-buy and Wedbush to outperform, while Truist and others adjusted price targets on the stock.
• The company reported a quarterly EPS loss of $0.45, missing expectations, while the shares traded at $26.40 and remain below both the 50-day and 200-day moving averages.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have received an average recommendation of "Buy" from the eleven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $66.00.

MAZE has been the subject of a number of research reports. Mizuho upgraded Maze Therapeutics to a "strong-buy" rating in a report on Wednesday, March 11th. Truist Financial cut their price objective on Maze Therapeutics from $68.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday, April 14th. BTIG Research reiterated a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, March 25th. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, Wedbush upped their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the stock an "outperform" rating in a report on Monday, March 16th.

Insider Transactions at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 2,500 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company's stock, valued at approximately $381,689.60. The trade was a 16.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business's stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the sale, the insider directly owned 10,503 shares of the company's stock, valued at approximately $266,461.11. This trade represents a 41.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 119,502 shares of company stock valued at $4,246,639 over the last quarter. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC increased its stake in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock worth $130,197,000 after buying an additional 2,390,713 shares during the period. Vanguard Group Inc. increased its stake in shares of Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company's stock worth $70,307,000 after buying an additional 362,060 shares during the period. Woodline Partners LP increased its stake in shares of Maze Therapeutics by 10.0% in the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company's stock worth $26,843,000 after buying an additional 94,529 shares during the period. Marshall Wace LLP increased its stake in shares of Maze Therapeutics by 9.0% in the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company's stock worth $35,111,000 after buying an additional 69,771 shares during the period. Finally, ArrowMark Colorado Holdings LLC increased its stake in shares of Maze Therapeutics by 40.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company's stock worth $31,793,000 after buying an additional 222,251 shares during the period.

Maze Therapeutics Price Performance

MAZE opened at $26.40 on Friday. The stock has a 50-day moving average price of $29.21 and a 200-day moving average price of $37.59. Maze Therapeutics has a 12-month low of $9.73 and a 12-month high of $53.65. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $1.46 billion, a P/E ratio of -10.43 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Equities analysts predict that Maze Therapeutics will post -2.74 earnings per share for the current fiscal year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.